US Small-Cap Q2 Batch: RDVT Beats as SMTI and NCMI Disappoint in Mixed Earnings Round

The Quick Take

• Red Violet Inc (RDVT) beat Q2 estimates with EPS of $0.35 and revenue hitting $26M, contrasting sharply with peers in the same batch
• Sanara MedTech (SMTI) reported EPS of -$0.04 and $28M revenue, raising valuation questions despite a forward-looking 'company performance overview'
• National CineMedia (NCMI) posted EPS of -$0.11 and $58M revenue, delivering solid performance amid what the company described as ongoing challenges

A mixed batch of US small-cap Q2 2026 earnings results illustrates the stark divergence between companies benefiting from AI-adjacent data analytics growth and those facing structural headwinds in healthcare technology and entertainment advertising. Red Violet's beat—driven by its identity intelligence and fraud analytics platform—stands in contrast to Sanara MedTech's continuing losses in wound care and NCMI's cinema advertising revenue pressures in a post-streaming competitive landscape. GuruFocus analysis across all three frames the same fundamental question: whether current valuations represent discounted opportunity or value traps given ongoing earnings pressure.

Red Violet's EPS beat at $0.35 on $26M revenue positions it as an outlier in the small-cap earnings season, with identity verification and data analytics remaining a structurally growing market as enterprises increase spending on fraud prevention. For Sanara MedTech, the -$0.04 EPS and $28M revenue reflect the capital intensity of scaling wound care technology penetration, where reimbursement cycles and hospital procurement timelines create earnings drag even when the underlying patient outcomes data is positive. NCMI's $58M revenue maintains scale in the cinema advertising market, though the ongoing challenges suggest that post-pandemic recovery is plateauing below pre-2020 advertiser demand.

Watch Red Violet's next quarterly guidance update to confirm whether the data analytics beat is a trend reversal or an isolated quarter, with particular attention to customer concentration risk and contract renewal rates. For Sanara MedTech, reimbursement approvals and expansion into new hospital systems are the key metrics to monitor as indicators of the company's path to profitability. The macro variable governing all three names is US consumer spending resilience: strong consumer spending supports cinema advertising revenue (NCMI), healthcare utilization (SMTI), and enterprise technology investment (RDVT), making any softening in the consumer outlook a triple headwind for the cohort.

Synthesized from 3 sources.